LRMR News & Analysis
2 articles
Market Mood
Larimar Therapeutics (LRMR) Submits BLA Module for Nomlabofusp Therapy
On June 29, Larimar Therapeutics Inc. (NASDAQ: LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA for its Nomlabofusp therapy, aiming for accelerated approval. The company plans to submit additional modules in the second half of 2026. The therapy demonstrated positive outcomes in an open-label study for treating Friedreich's ataxia, with confirmed sufficient data for application approval based on a new surrogate endpoint. Analyst Christopher Chen from Baird reduced the target price from $7 to $5, indicating a potential upside of over 53% from current levels for investors.
Read More: Larimar Therapeutics (LRMR) Submits BLA Module for Nomlabofusp Therapy
Larimar Therapeutics (LRMR) Stock Rises After Insider Purchase
Larimar Therapeutics (LRMR) experienced a notable increase in stock price following an insider purchase. The specific details of the stock jump were not disclosed, but insider purchases are often viewed positively by investors. This increase highlights the confidence that insiders have in the company's future performance. For ordinary investors, insider purchases can be a signal of potential growth and may influence investment decisions.
Read More: Larimar Therapeutics (LRMR) Stock Rises After Insider Purchase